Precision medicine in inflammatory bowel disease

Area of Science:

• Gastroenterology and Immunology
• Precision Medicine
• Molecular Biology

Background:

• Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), is a chronic condition with unpredictable relapse patterns.
• IBD management is challenging due to disease heterogeneity, potential complications, and the need for effective induction and maintenance therapies.
• Current treatments offer variable efficacy, highlighting the need for personalized approaches.

Purpose of the Study:

• To review the role of precision medicine in managing IBD.
• To discuss predictive markers for disease progression and therapeutic response in IBD patients.
• To explore monitoring indices for optimizing treatment through therapeutic drug monitoring.

Main Methods:

• Literature review of recent advances in IBD genetics, pharmacogenetics, proteomics, and microbiome research.
• Analysis of molecular markers associated with disease prognosis and treatment efficacy.
• Examination of indices used in therapeutic drug monitoring for IBD.

Main Results:

• Genetics, pharmacogenetics, proteomics, and microbiome studies are identifying key molecular markers.
• These markers show promise in predicting individual patient prognosis and response to specific therapies.
• Therapeutic drug monitoring indices can aid in optimizing treatment regimens.

Conclusions:

• Precision medicine holds significant potential to revolutionize IBD management.
• Identifying predictive markers will enable more effective and personalized treatment strategies.
• Improved patient outcomes and reduced healthcare costs are anticipated with the integration of precision medicine in IBD care.